Critical Survey: Blue Owl Capital Co. III (NYSE:OBDE) and Cybin (OTCMKTS:CLXPF)

Blue Owl Capital Co. III (NYSE:OBDE) and Cybin (OTCMKTS:CLXPF) are both small-cap finance companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.

Profitability

This table compares Blue Owl Capital Co. III and Cybin’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Blue Owl Capital Co. III	63.33%	13.62%	6.78%
Cybin	N/A	N/A	N/A

Earnings & Valuation

This table compares Blue Owl Capital Co. III and Cybin’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blue Owl Capital Co. III	$422.83 million	4.30	$271.96 million	$2.27	6.50
Cybin	$680,000.00	659.95	-$24.42 million	($0.24)	-12.58

Blue Owl Capital Co. III has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Blue Owl Capital Co. III, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

0.0% of Cybin shares are owned by institutional investors. 90.8% of Blue Owl Capital Co. III shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Blue Owl Capital Co. III and Cybin, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blue Owl Capital Co. III	0	0	1	0	3.00
Cybin	0	0	0	0	N/A

Blue Owl Capital Co. III currently has a consensus price target of $16.00, suggesting a potential upside of 8.47%. Given Blue Owl Capital Co. III’s higher probable upside, research analysts clearly believe Blue Owl Capital Co. III is more favorable than Cybin.

Summary

Blue Owl Capital Co. III beats Cybin on 10 of the 12 factors compared between the two stocks.

About Blue Owl Capital Co. III

Blue Owl Capital Corporation is a specialty finance company focused on lending to U.S. middle-market companies. Blue Owl Capital Corporation is based in NEW YORK.

About Cybin

Cybin Inc., a life sciences company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products. The Natures Journey segment focuses on non-psychedelic medical mushroom nutraceutical products. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.